SOURCE: Paragon Financial Limited

Paragon Financial Limited

November 16, 2011 08:16 ET

Volatile Nature of Biotechnology Industry Weighs on Amarin Corporation and Alimera Sciences

The Paragon Report Provides Equity Research on Amarin Corporation & Alimera Sciences

NEW YORK, NY--(Marketwire - Nov 16, 2011) - Drug approvals from administrative bodies in both the U.S. and Europe have been pivotal for biotech companies recently. Investors have been particularly sensitive to decisions made on new drugs considering the state of the global economic recovery. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Amarin Corporation PLC (NASDAQ: AMRN) and Alimera Sciences, Inc. (NASDAQ: ALIM). Access to the full company reports can be found at:

While there are some success stories in the industry, a number of players are having trouble dealing with the volatile nature of biotechnologies. Research and development costs are extremely high, and the success of a product can sometimes not be measured until late in development. According to Krishan Maggon, a Geneva-based pharmaceuticals consultant, the number of new biotech drugs approved in the U.S. has remained in the 20 to 25 range during the past four years, while in Europe the figure was a record-low 14 last year.

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at and get exclusive access to our numerous stock reports and industry newsletters.

Amarin Corporation is a late-stage biopharmaceutical company with a focus on cardiovascular disease. Amarin is aggressively pursuing a patent strategy to bolster the proprietary position of AMR101. The Company has filed and is actively prosecuting numerous patents. Amarin has filed 16 pending U.S. patent applications belonging to 11 US patent families that collectively include numerous independent claims and dependent claims. In September 2011, Amarin submitted an NDA to the FDA requesting approval to market and sell AMR101 for the indication studied in the Phase 3 MARINE trial.

Alimera Sciences is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Shares of the company were crushed earlier this month after the Food and Drug Administration refused to approve Iluvien, a time-release injection that is intended to treat diabetic macular edema, which can cause blurred vision and blindness. Alimera said it still plans to seek approval for Iluvien in the European Union.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at